title: Response to letter to the editor: long-term visual outcome and prognostic factors of intravitreal antivascular endothelial growth factor treatment for retinal angiomatous proliferation.
authors.affiliation: Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, 156, 4ga, Yeoungdeungpo-dong, Yeoungdeungpo-gu, Seoul, South Korea.
authors.forename: Han Joo
authors.initials: HJ
authors.lastname: Cho
authors.affiliation: Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, 156, 4ga, Yeoungdeungpo-dong, Yeoungdeungpo-gu, Seoul, South Korea. kjh7997@daum.net.
authors.forename: Tae Gon
authors.initials: TG
authors.lastname: Lee
authors.affiliation: Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, 156, 4ga, Yeoungdeungpo-dong, Yeoungdeungpo-gu, Seoul, South Korea.
authors.forename: Jong Woo
authors.initials: JW
authors.lastname: Kim
mesh_terms: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016228:Endothelial Growth Factors; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D011379:Prognosis; D000069579:Ranibizumab; D012160:Retina; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity; D057135:Wet Macular Degeneration
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D016228:Endothelial Growth Factors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
references.citation: Ophthalmology. 2014 Jan;121(1):150-61
references.pmid: 24084496
references.citation: Ophthalmology. 2014 May;121(5):1079-91
references.pmid: 24433969
references.citation: Graefes Arch Clin Exp Ophthalmol. 2016 Jan;254(1):23-30
references.pmid: 25825231